Merit Medical Systems (NASDAQ:MMSI) Price Target Cut to $103.00 by Analysts at Barrington Research

Merit Medical Systems (NASDAQ:MMSI - Free Report) had its price target lowered by Barrington Research from $111.00 to $103.00 in a report released on Friday, Marketbeat Ratings reports. The brokerage currently has an outperform rating on the medical instruments supplier's stock. Barrington Research also issued estimates for Merit Medical Systems' Q2 2025 earnings at $0.88 EPS, Q3 2025 earnings at $0.80 EPS, Q4 2025 earnings at $0.80 EPS, Q1 2026 earnings at $0.81 EPS, Q2 2026 earnings at $1.05 EPS, Q3 2026 earnings at $0.91 EPS, Q4 2026 earnings at $0.94 EPS and FY2027 earnings at $4.05 EPS.

Several other research analysts have also issued reports on the company. Needham & Company LLC reiterated a "buy" rating and set a $116.00 price objective on shares of Merit Medical Systems in a research note on Wednesday, April 9th. Raymond James increased their price objective on Merit Medical Systems from $105.00 to $110.00 and gave the stock an "outperform" rating in a research note on Tuesday, December 31st. Wells Fargo & Company dropped their price objective on Merit Medical Systems from $120.00 to $117.00 and set an "overweight" rating for the company in a research note on Wednesday, February 26th. Robert W. Baird decreased their target price on Merit Medical Systems from $111.00 to $110.00 and set an "outperform" rating on the stock in a report on Friday, April 25th. Finally, Piper Sandler decreased their target price on Merit Medical Systems from $116.00 to $112.00 and set an "overweight" rating on the stock in a report on Wednesday, April 23rd. Two analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $107.78.

Merit Medical Systems Stock Performance

Shares of MMSI traded down $0.36 during mid-day trading on Friday, hitting $94.40. The company's stock had a trading volume of 140,152 shares, compared to its average volume of 500,656. Merit Medical Systems has a one year low of $73.67 and a one year high of $111.45. The company has a debt-to-equity ratio of 0.57, a quick ratio of 3.82 and a current ratio of 5.36. The firm has a market capitalization of $5.58 billion, a PE ratio of 46.27, a price-to-earnings-growth ratio of 2.34 and a beta of 0.85. The stock's 50-day moving average is $98.16 and its two-hundred day moving average is $100.56.

Merit Medical Systems (NASDAQ:MMSI - Get Free Report) last issued its earnings results on Thursday, April 24th. The medical instruments supplier reported $0.86 EPS for the quarter, beating analysts' consensus estimates of $0.75 by $0.11. The business had revenue of $355.35 million during the quarter, compared to analyst estimates of $352.57 million. Merit Medical Systems had a return on equity of 15.61% and a net margin of 9.05%. Merit Medical Systems's revenue was up 9.8% on a year-over-year basis. During the same period in the prior year, the company posted $0.77 earnings per share. As a group, sell-side analysts anticipate that Merit Medical Systems will post 3.37 EPS for the current year.

Insiders Place Their Bets

In other news, CEO Fred P. Lampropoulos sold 31,320 shares of the stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $103.86, for a total transaction of $3,252,895.20. Following the completion of the sale, the chief executive officer now owns 1,086,028 shares of the company's stock, valued at $112,794,868.08. This represents a 2.80 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Brian G. Lloyd sold 30,000 shares of the stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $102.90, for a total transaction of $3,087,000.00. Following the sale, the insider now directly owns 38,945 shares of the company's stock, valued at $4,007,440.50. This represents a 43.51 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 109,132 shares of company stock worth $11,139,521. Company insiders own 3.70% of the company's stock.

Institutional Investors Weigh In On Merit Medical Systems

Several large investors have recently made changes to their positions in the stock. Opal Wealth Advisors LLC bought a new position in Merit Medical Systems in the first quarter valued at $31,000. NewSquare Capital LLC acquired a new stake in shares of Merit Medical Systems in the fourth quarter valued at about $32,000. Versant Capital Management Inc increased its position in shares of Merit Medical Systems by 1,518.5% in the first quarter. Versant Capital Management Inc now owns 437 shares of the medical instruments supplier's stock valued at $46,000 after acquiring an additional 410 shares during the last quarter. Kohmann Bosshard Financial Services LLC acquired a new stake in shares of Merit Medical Systems in the fourth quarter valued at about $52,000. Finally, Federated Hermes Inc. increased its position in shares of Merit Medical Systems by 139.1% in the fourth quarter. Federated Hermes Inc. now owns 655 shares of the medical instruments supplier's stock valued at $63,000 after acquiring an additional 381 shares during the last quarter. Institutional investors own 99.66% of the company's stock.

About Merit Medical Systems

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.